Literature DB >> 11066188

Evaluating patients with arthritis of recent onset: studies in pathogenesis and prognosis.

H S El-Gabalawy1, P Duray, R Goldbach-Mansky.   

Abstract

Inflammatory synovitis of recent onset poses a diagnostic and prognostic challenge to primary care physicians and rheumatologists. A lack of understanding of the underlying etiologic and pathogenic processes limits the ability to distinguish forms of arthritis that follow a benign, self-limiting course from forms that proceed to an aggressive, erosive disease requiring intensive immunosuppressive therapy. It is estimated that between 30% and 40% of patients presenting with early synovitis have disease that remains unclassified. Using data from a cohort of patients with early synovitis and reviewing current literature, we discuss investigational approaches toward a new classification of patients with early synovitis. Although a lack of understanding of this heterogeneous clinical syndrome has led clinicians to take a largely empirical approach to treatment thus far, the evolving awareness of disease predisposition at a genetic level and the expanding ability to specifically manipulate biological pathways may ultimately change the approach to this clinical problem. JAMA. 2000;284:2368-2373.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11066188     DOI: 10.1001/jama.284.18.2368

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  2 in total

1.  A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis.

Authors:  Pierre-Antoine Gourraud; Philippe Dieudé; Jean-Frédéric Boyer; Leonor Nogueira; Anne Cambon-Thomsen; Bernard Mazières; François Cornélis; Guy Serre; Alain Cantagrel; Arnaud Constantin
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 2.  Autoantibodies in normals--the value of predicting rheumatoid arthritis.

Authors:  Thomas Dörner; Arne Hansen
Journal:  Arthritis Res Ther       Date:  2004-10-15       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.